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Background
The overexpression of Aurora A kinase (AurA) has been reported in various malignancies, 
including acute myeloid leukemia (AML). However, the expression of AurA and the effects 
of AurA inhibition in cancer stem cells are not yet fully understood. We investigated the 
expression and inhibition of AurA in AML stem cells (CD34＋/CD38−).
Methods
Expression of AurA was investigated in cell lines (NB4 and KG1) that express high levels 
of CD34 and low levels of CD38. Primary AML cells were harvested from 8 patients. The 
expression of AurA and cell death induced by inhibition of AurA were analyzed in CD34＋/ 
CD38− cells.
Results
AurA was shown to be overexpressed in both primary AML cells and leukemia stem cells 
(LSCs) compared to normal hematopoietic stem cells. Inhibition of AurA plus cytarabine 
treatment in LSCs resulted in increased cytotoxicity compared to cytarabine treatment 
alone. Additional stimulation with granulocyte-colony stimulating factor (G-CSF) in-
creased the cell death caused by AurA inhibition plus cytarabine treatment.
Conclusion
To our knowledge, this is the first report describing increased expression of AurA in LSCs. 
Our results suggest that selective AurA inhibition may be used to reduce LSCs, and this 
reduction may be enhanced by stimulation with G-CSF. Further exploration of relationship 
between nuclear factor kappa-B and AurA inhibition and the potential of AurA inhibition 
for use in leukemia treatment is needed.
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INTRODUCTION
Aurora kinases are a family of serine/threonine kinases 
that play essential roles in chromosome alignment, separa-
tion, and cytokinesis during mitosis and cell division [1, 
2]. The overexpression of Aurora A kinase (AurA) leads 
to the amplification of centrosomes, inhibition of cytokinesis, 
and aneuploidy, which can be observed in various human 
cancers, including hepatocellular carcinoma, ovarian carci-
noma, and hematological malignancies [3-7]. Although data 
on the roles of AurA in malignancy are accumulating and 
selective Aurora kinase inhibitors are under development 
in clinical trials [8, 9], the role of AurA in cancer stem 
cells has not been fully investigated. Thus far, reports on 
AurA in cancer stem cells examined malignancies of epi-
thelial origin; AurA inhibition resulted in reduced activity 
of nuclear factor kappa-B (NF-κB) and anti-apoptotic Bcl-2 
family members [10, 11].
Acute myeloid leukemia (AML) is a heterogeneous group 
of clonal hematopoietic neoplasms. Most patients achieve 
complete remission after a single round of chemotherapy, 
but nearly half of the patients relapse, and only 20-30% 
of patients achieve long-term disease-free survival. Relapse 
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is related to residual disease and development of chemo-
therapy resistance. Leukemia stem cells (LSCs) are thought 
to have the capacity of self-renewal and the ability to initiate 
and maintain leukemia; thus, these cells may underlie relap-
ses in AML. LSCs are widely hypothesized to exist as a 
small population among the CD34＋/CD38− fraction of leuke-
mia cells. CD44, CLL-1, and CD96 are also increased in 
LSCs. LSCs exhibit intrinsic resistance to treatment, which 
is attributed to their quiescent state and to the increased 
expression of abnormal drug transporters [12, 13].
We previously reported the enhancement of cytarabine 
(Ara-C)-induced cell death by AurA inhibition in leukemia 
cell lines. Cell death was increased by a non-caspase-depend-
ent mitotic catastrophe [14]. To define AurA expression in 
LSCs and to identify the effects of AurA inhibition on the 
reduction of LSCs, we investigated the effect of selective 
AurA inhibition in LSCs from AML patients.
MATERIALS AND METHODS
1. Cell isolation, culture, and treatment
The human leukemia cell lines, KG1 (American Type 
Culture Collection, Manassas, VA, USA) and NB4 (DSMZ 
- German Collection of Microorganisms and Cell Cultures), 
and primary AML cells isolated from patients were used. 
Bone marrow mononuclear cells were isolated from anti-
coagulated bone marrow specimens aspirated from patients 
by Ficoll-Hypaque density gradient centrifugation. Cells 
were cultured in RPMI-1640 (Life Technologies, Grand 
Island, NY, USA) supplemented with 10% heat-inactivated 
fetal bovine serum (HyClone Laboratories, Logan, UT, USA) 
and 1% penicillin/streptomycin (Invitrogen Corporation, 
Carlsbad, CA, USA) in a humidified atmosphere containing 
5% CO2 at 37oC. Growing cells were treated with different 
concentrations of clinical-grade Ara-C (Pharmacia/Upjohn, 
St. Quentin, France) alone or in combination with the Aurora 
kinase inhibitor, C1368 (Sigma-Aldrich, St. Louis, MO, USA).
2. Antibodies
Mouse monoclonal antibodies against poly ADP-ribose 
polymerase (PharMingen, San Diego, CA, USA) and α-tubu-
lin (Upstate Biotechnology, Lake Placid, NY, USA) were 
used. Rabbit polyclonal antibodies against phospho(p)-AurA, 
Wnt-1, beta-catenin, Gli-1, Gli-2, p-Akt, p-MEK, p-ERK, 
p-p38 (Cell Signaling Technology, Beverly, MA, USA), cas-
pase-3 (PharMingen), and NF-κB (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) were used.
3. Assessment of cell viability and apoptosis
To assess the viability of LSCs, cells were labeled with 
anti-CD34-ECD (BD Biosciences) and anti-CD38-PerCP 
(PharMingen) for 30 min, and then resuspended in phos-
phate-buffered saline (PBS) containing 50 μg/mL propidium 
iodide (PI; Sigma-Aldrich, St. Louis, MO, USA), prior to 
flow cytometric analysis. Cell death was defined based on 
changes in the permeability of PI. Trypan blue staining and 
light microscopic examination were also used for assessing 
cell viability. Apoptosis was detected with an annexin 
V-binding assay and flow cytometric analysis. Labeled cells 
were resuspended in 100 μL of annexin V-binding buffer 
and incubated with annexin V-fluorescein isothiocyanate 
and anti-7-aminoactinomycin (Beckman Coulter) for 20 min 
at room temperature prior to flow cytometric analysis. The 
percentage of apoptotic cells was determined by quantifying 
the annexin V-positive cells using gates set for total ungated 
cells, CD34＋/CD38− cells, and CD34＋/CD38＋ cells by flow 
cytometric analysis on a FACSCalibur flow cytometer (Bec-
ton Dickinson Immunocytometry Systems, BDIS, San Jose, 
CA, USA).
4. Cell cycle analysis
After the indicated treatments, cells were harvested, wash-
ed with PBS, and fixed in 70% ethanol at −20oC for 16 
h. Fixed cells were washed twice with PBS, and resuspended 
in cell cycle buffer (0.38 mM sodium citrate, 0.5 mg/mL 
RNase A, 0.01 mg/mL PI) at a concentration of 1×106 cells/mL. 
Cell cycle analysis was performed by flow cytometric 
analysis.
5. Western blot analysis
Cells were lysed in 100 μL of lysis buffer and sonicated 
briefly. Homogenized lysates were quantified with a Bio-Rad 
protein assay (Bio-Rad Laboratories, Hercules, CA, USA). 
Equal amounts of protein (20 μg) were boiled for 10 min, 
separated by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis, and transferred to nitrocellulose membranes. 
After blocking in 0.05% PBS-T and 5% bovine serum albumin 
for 1 h, the membranes were incubated with primary anti-
bodies for 2 h at room temperature. The membranes were 
then washed 4 times in PBS-T and incubated with horse-
radish peroxidase-conjugated secondary antibodies (Cell 
Signaling Technology) for 1 h at room temperature. They 
were then washed with Tris-buffered saline with Tween, 
and proteins were visualized using enhanced chemilumine-
scence (Amersham Bioscience). Quantitative densitometric 
analysis was performed using a luminescent image analyzer 
(LAS-1000 Plus, Fuji Film, Ltd.) and TINA software version 
2.10e (Raytest Isotopenmessgeraete GmbH, Straubenhardt, 
Germany).
6. Statistical analysis
Statistical analysis was performed using the Student’s 
t-test. Differences were defined as statistically significant 
when P＜0.05. Values are expressed as mean±standard 
deviation.
RESULTS
1. Effect of Ara-C and an the AurA inhibitor on the NB4 leuke-
mia cell line
We examined the sensitivity of the NB4 leukemia cell 
line to single treatment with Ara-C or an the AurA inhibitor, 
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Fig. 1. Ara-C- or AurA inhibition-induced cell death in the NB4 cell 
line. (A) NB4 cells were incubated with different concentrations of 
Ara-C and AurA inhibitor for 48 h. After treatment, cell prolifera-
tion was analyzed as described. (B) The proportions of apoptotic 
cells after treatment with Ara-C or AurA inhibitor at various 
concentrations for 48 h (P＞0.05 for all concentrations). (C) 
Representative histogram of cell cycle analysis after treatment 
with various concentrations of Ara-C or AurA inhibitor (P＞0.05 
for all concentrations).
and to co-treatment with both Ara-C and the AurA inhibitor. 
Cells were treated with different concentrations of Ara-C 
or the AurA inhibitor for 48 h. Cell proliferation, apoptosis, 
and cell cycle analyses were performed. Inhibition of cell 
proliferation was first detected in Ara-C-treated cultures 
at 1 μM (60.5±7.5%) and in AurA-treated cells at 5 μM 
(52.15±8.3%, Fig. 1A). Both Ara-C and the AurA inhibitor 
increased the proportion of apoptotic cells in a dose-depend-
ent manner (Fig. 1B). Cell cycle analysis revealed that the 
fraction of sub-G1 phase cells began to increase at the same 
concentration at which apoptosis started to increase (Fig. 
1C).
2. Ara-C/the AurA inhibitor co-treatment enhanced cell death 
in the NB4 leukemia cell line
To determine the optimal co-treatment concentrations 
of Ara-C and the AurA inhibitor, we identified concen-
trations of the AurA inhibitor that reduced p-AurA ex-
pression during co-treatment with Ara-C by western 
blotting. At an the AurA inhibitor concentration of 2 μM, 
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Fig. 2. Effect of co-treatment with Ara-C and AurA inhibitor in NB4 cells. (A) Expression of p-AurA and total AurA protein after co-treatment with 
Ara-C (1 μM) and various concentrations of AurA inhibitor (0, 1, 2, and 4 μM) for 48 h. (B) Analysis of apoptosis after co-treatment with Ara-C (1 
μM) and AurA inhibitor (2 μM). a)P＜0.05, b)P＜0.05. (C) Cell cycle analysis after co-treatment with Ara-C (1 μM) and AurA inhibitor (2 μM). a)P
＜0.05, b)P＜0.05.
Fig. 3. Effect of Ara-C/AurA inhibitor co-treatment on the expression of caspase-3 and components of the Wnt/β-catenin, hedgehog, Akt/PKB, and 
MAPK pathways. (A) After co-treatment, NB4 cell lysates were subjected to western blotting to assess the expression of p-AurA and the cleavage 
of PARP. (B) After co-treatment, NB4 cell lysates were subjected to western blotting to assess the expression of Wnt-1, β-catenin, Gli-1, and Gli-2. 
(C) Expression of Akt, MEK, and ERK after co-treatment with Ara-C/AurA inhibitor.
both p-AurA and total AurA protein expression were de-
creased (Fig. 2A). Then, NB4 cells were co-treated with 
1 μM of Ara-C and 2 μM of the AurA for 48 h and analyzed 
for apoptosis and cell cycle characteristics. Co-treatment in-
creased the rate of apoptosis compared to Ara-C alone or 
the AurA inhibitor alone (co-treatment, 66.23±11.93%; 
Ara-C alone, 25.38±2.45%; the AurA inhibitor, 13.82±1.82%; 
P＜0.05; Fig. 2B). The proportion of cells in sub-G1 phase 
increased more in co-treated cells (co-treatment, 65.5±1.74%; 
Ara-C alone, 31.17±0.72%; the AurA inhibitor alone, 20.96± 
4.17%; P＜0.05; Fig. 2C).
We previously reported that Ara-C/the AurA inhibitor 
induced mitochondria-mediated, caspase-dependent apopto-
sis in Ara-C-sensitive cell lines, and non-caspase-dependent 
mitotic catastrophe in Ara-C-resistant cell lines. To identify 
changes in signaling pathways in cancer stem cells treated 
with Ara-C and the the AurA inhibitor, we examined the 
expression of p-Akt, p-MEK, p-ERK, Wnt, β-catenin, Gli-1, 
and Gli-2 by western blot analysis after co-treatment of 
NB4 cells. Expression of Wnt1 and β-catenin decreased syn-
ergistically (Fig. 3B), while p-Akt, p-MEK, and p-ERK were 
further decreased by co-treatment (Fig. 3C). However, no 
synergistic effect of co-treatment was observed for Gli ex-
pression (Fig. 3B).
3. AurA expression in normal hematopoietic stem cells and 
LSCs
To examine the expression of AurA kinase in LSCs, we 
used primary AML cells from patients. Primary AML cells 
were divided into 2 groups, CD34＋/CD38− cells (LSCs＋) 
containing LSCs and CD34＋/CD38＋ cells (LSCs−), by im-
munophenotyping based on the expression of CD34 and 
CD38 (Fig. 4A). Compared to normal hematopoietic stem 
cells (HSCs), primary AML cells showed higher expression 
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Fig. 4. Expression of AurA kinase in primary AML cells and normal hematopoietic cells. (A) Expression of AurA in subpopulations of CD34＋/CD38−
cells (LSCs＋) containing LSCs and CD34＋/CD38＋ cells (LSCs−) containing non-LSC blasts, analyzed by flow cytometry. (B) Expression of AurA in 
normal hematopoietic stem cells analyzed by flow cytometry. (C) Comparison of AurA expression in normal hematopoietic stem cells, CD34＋/ 
CD38− cells, and CD34＋/CD38＋ cells. Symbols indicate the expression level in each specimen; bar indicates mean. a)P＜0.05, b)P＜0.05, c)P＜0.05.
of AurA (normal, 4.7±2.27%; primary AML cells, 59.95± 
6.58%; Fig. 4A, B). The proportion of LSCs＋ comprising 
LSCs was 10.55±5.33%. Both LSCs＋ and LSCs− cells showed 
significantly higher expression of AurA compared to normal 
HSCs. In addition, LSCs− cells showed higher expression 
of AurA than did normal HSCs (LSCs＋, 29.86±4.85%; LSCs−, 
61.59±10.07%; Fig. 4C).
4. Increased cell death in LSCs＋ induced by Ara-C/the AurA 
inhibitor co-treatment and granulocyte-colony stimulat-
ing factor (G-CSF)
Primary AML cells and normal bone marrow CD34＋ cells 
were treated with Ara-C and the AurA inhibitor for 48 
h and analyzed for cell death. Cell death was not increased 
by co-treatment in normal CD34＋ cells, but co-treated pri-
mary AML cells showed markedly increased cell death com-
pared to single treatment with Ara-C or the AurA inhibitor. 
The cell death rate in co-treated primary AML cells was 
71.12±8.01%, compared to 32.64±4.09% for LSCs＋ cells and 
48.7±3.02% for LSCs− cells (Fig. 5A). To increase cytotoxicity 
in LSCs＋ cell populations, G-CSF was administered before 
Ara-C/the AurA inhibitor co-treatment. Expression of AurA 
in LSCs＋ cells increased from 32.14±0.7% to 48.19±1.92% 
(Fig. 5B). G-CSF-stimulated primary AML cells were then 
treated with Ara-C and the AurA inhibitor alone or in 
combination. Cell death in the co-treated LSCs＋ population 
increased after G-CSF stimulation compared to single treat-
ment with Ara-C or the AurA inhibitor (Fig. 5C, G-CSF 
stimulation, 50.30±1.87%; non-G-CSF, 32.64±2.71%).
5. Ara-C-induced cell death is related to p38 mitogen-activ-
ated protein kinase (p38MAPK) and NF-κB activation and 
might be related to decreased apoptosis induced by the 
AurA inhibitor in KG1 cells
In our previous report, we found that Ara-C-induced cell 
death is related to p38MAPK; our current data are consistent 
with that observation (Fig. 6A, B). Induction of apoptosis 
by Ara-C was similar in NB4 cells and KG1 cells, but responses 
to the AurA inhibitor were different. Specifically, the ex-
pression of NF-κB as detected by western blot analysis dif-
fered between NB4 and KG1 cells (Fig. 6D). NF-κB expression 
was decreased by Ara-C treatment in NB4 cells but was 
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Fig. 5. Effect of Ara-C/the AurA inhibitor co-treatment on primary AML cells and normal hematopoietic cells, and effect of G-CSF priming on this
co-treatment. Primary leukemia cells from patients were treated with Ara-C (1 μM)±the AurA inhibitor (2 μM) for 48 h. (A) Cells were evaluated
for apoptosis by flow cytometry in total cells, CD34＋/CD38− cells, and CD34＋/CD38＋ cells, and compared to normal CD34＋ hematopoietic stem
cells. Bars indicate SD. (B) Primary CD34＋/CD38− cells containing LSCs were stimulated with G-CSF (1 μg/mL) for 7 days and analyzed for 
expression of AurA. Bars indicate SD. (C) CD34＋/CD38− cells were stimulated with G-CSF for 7 days and then treated with or without Ara-C and
the AurA inhibitor. Evaluation of apoptosis was performed by flow cytometry. Bars indicate SD.
unaffected by the same treatment in KG1 cells.
DISCUSSION
Resistance to cytotoxic agents is one of the obstacles in 
the treatment of AML. We found that combined AurA in-
hibition and Ara-C treatment enhanced leukemic cell death 
in Ara-C-resistant leukemia cells by inducing apoptosis and 
mitotic catastrophe [14]. Because LSCs are also a major cause 
of relapse and resistance to treatment, we explored the effects 
of AurA inhibition in LSCs.
AurA is overexpressed in various cancers, including hema-
tological malignancies [3-5, 8], and its overexpression is re-
lated to progression or poor prognosis subtypes in some ma-
lignancies [4, 6, 7, 15]. Therefore, inhibition of AurA by 
selective inhibitors is the subject of several clinical trials. 
However, AurA expression and the effects of AurA inhibition 
in cancer stem cells are not yet fully understood. In a few 
reports on cancer stem cells of epithelial origins, AurA ex-
pression was found to be upregulated, and inhibition of AurA 
led to cell cycle arrest or restricted cell growth [10, 11].
Most LSCs are known to exist as a fraction of the CD34＋/ 
CD38− population and are able to transmit AML to nonobese 
diabetic/severe combined immunodeficient mice [16]. Our 
data show that a CD34＋/CD38− subpopulation of primary 
AML cells that contains LSCs exhibited significantly in-
creased expression of AurA when compared to normal HSCs. 
Similarly, Ye et al. reported increased AurA expression in 
CD34＋ blast cells from patients with AML or myelodysplastic 
syndrome [17]. Because the CD34＋ population includes 
non-LSC blasts, to our knowledge, this is the first report 
on AurA expression in LSCs. As expected, AurA expression 
was high in non-LSC blast cells, which may be because 
non-LSC blasts are actively cycling, whereas the majority 
of LSCs are quiescent. Similar results have been seen in 
colorectal cancer stem cells (CR-CSC) and ovarian cancer 
stem cells (EOC stem cells) [10, 11]. Cammareri et al. [10] 
found that the expression of AurA in CR-CSC was lower 
than that in primary colorectal cancer cells. However, in 
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Fig. 6. Effect of Ara-C and the AurA inhibitor on NB4 and KG1 cells in relation to p38 MAP kinase activation and NF-κB protein. (A) Cells were treated
with various concentrations (0.01, 0.1, 1, 5, and 10 μM) of Ara-C for 48 h, after which apoptosis was evaluated by flow cytometry. (B) Expression 
of p38 and phospho-p38 was evaluated after Ara-C (2 μM) treatment. Cells were treated with a selective inhibitor of p38, SB203580 (20 μM), for 
3 h; next, the rates of apoptosis were compared. (C) NB4 and KG1 cells were treated with various concentrations of Ara-C or the AurA inhibitor (0.01,
0.1, 1, 5, and 10 μM) and then evaluated for apoptosis by flow cytometry. (D) Expression of NF-κB evaluated by western blot analysis.
our findings, LSCs expressed a significantly higher level of 
AurA than did normal HSCs, and upon AurA inhibition, 
LSCs showed increased apoptosis while AurA inhibition 
caused no changes in apoptosis in normal HSCs. We think 
this difference between normal HSCs and LSCs may be useful 
for developing treatments that target LSCs.
The role of AurA in LSCs is not yet fully defined. AurA 
exerted no transforming activity in normal colon cells by 
itself, but induced centrosomal amplification, which can re-
sult in oncogenesis with additional genetic changes [10]. 
Although the function of AurA in LSC survival has not 
been fully analyzed, experiments in both CR-CSC and EOC 
stem cells showed that silencing or inhibition of AurA was 
related to a decreased G1 phase population and an increased 
number of cells in G2/M arrest. Our results in LSCs were 
similar. Selective AurA inhibition increased the sub-G1 phase 
fraction in NB4 cells, and in K562, KG1, and U937 cells 
in another study [14].
Our previous report focused on the synergistic effects of 
Ara-C and the AurA inhibitor in leukemia cells and its effects 
on related molecular pathways. Here, we examined the ef-
fects of selective AurA inhibition on LSC survival. CD34＋/ 
CD38− populations containing LSCs, obtained from AML 
patients, showed increased apoptosis after treatment with 
either Ara-C or the AurA inhibitor, and the effect was sig-
nificantly enhanced upon co-treatment with Ara-C and the 
AurA inhibitor. This co-treatment effect was greater in 
non-LSCs. Following stimulation with G-CSF, AurA ex-
pression increased, leading to enhanced apoptosis with 
Ara-C/AurA co-treatment. Because the main roles of AurA 
are in spindle formation, centrosome maturation, and dupli-
cation [2], this result may indicate that G-CSF stimulated 
some LSCs to enter the cell cycle or increased asymmetric 
cell division.
KG1 cells exhibited lower rates of apoptosis compared 
to NB4 cells following AurA inhibitor treatment. In both 
cell lines, Ara-C-induced cell death involved the activation 
of p38MAPK. In KG1 cells, NF-κB was constitutively acti-
vated after Ara-C treatment, perhaps explaining the lower 
apoptosis rates in these cells. In EOC stem cells [11], selective 
AurA inhibition resulted in reduced NF-κ activation. 
Guzman et al. reported increased NF-κB levels in CD34＋ 
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human AML cells [18], and Colado et al. tested bortezomib 
as an NF-κB inhibitor to overcome drug resistance in CD34＋ 
immature myeloid leukemia cells [19]. Reduced apoptosis 
in KG1 cells induced by AurA inhibition may result from 
insufficient NF-κB inhibition. Because NF-κB activation lev-
els differ in various cancers, the required dose of AurA in-
hibitor may vary among cell lines. Nevertheless, taken to-
gether, these results suggest that AurA inhibition and potent 
NF-κB activation can reduce the number of LSCs.
In summary, our study demonstrated increased expression 
of AurA in LSCs. Furthermore, our findings suggest the possi-
bility that selective AurA inhibitors can be used to reduce 
the numbers of LSCs, an effect that can be enhanced by 
stimulation with G-CSF. Further exploration of the relation-
ships between NF-κB and AurA inhibition, and the potential 
utility of AurA inhibition in leukemia treatment is needed.
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